WallStSmart

Genasys Inc (GNSS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 409% more annual revenue ($258.90M vs $50.88M). ZEPP leads profitability with a -15.5% profit margin vs -29.2%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

GNSS

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GNSSUndervalued (+66.7%)

Margin of Safety

+66.7%

Fair Value

$5.98

Current Price

$1.87

$4.11 discount

UndervaluedFair: $5.98Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GNSS1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
145.9%10/10

Revenue surging 145.9% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

GNSS4 concerns · Avg: 2.3/10
Market CapQuality
$86.81M3/10

Smaller company, higher risk/reward

Price/BookValuation
46.8x2/10

Trading at 46.8x book value

Return on EquityProfitability
-191.9%2/10

ROE of -191.9% — below average capital efficiency

EPS GrowthGrowth
-92.4%2/10

Earnings declined 92.4%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : GNSS

The strongest argument for GNSS centers on Revenue Growth. Revenue growth of 145.9% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : GNSS

The primary concerns for GNSS are Market Cap, Price/Book, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

GNSS is growing revenue faster at 145.9% — sustainability is the question.

Monitor SCIENTIFIC & TECHNICAL INSTRUMENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 31/100) and 43.0% revenue growth. GNSS offers better value entry with a 66.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Genasys Inc

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

Genasys Inc., a communications company, designs, develops and markets multi-directional and targeted audio technologies, voice transmission products, and location-based mass messaging solutions for emergency alerts and workforce management globally. The company is headquartered in San Diego, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?